Lowest Price Guaranteed From USD 5,899
Published
July 2021
Pages
250
View Count
3854
Example Insights
Report Description
Human epidermal growth factor receptor 2 (HER2), a member of human epidermal growth factor receptor family, plays an important role in the development and progression of various types of cancers, especially breast cancer. Over time, it has been found to be an important target for the drug therapies intended for treating various types of breast cancer. HER2 targeting therapies have shown to be a promising treatment option, capable of preventing tumor cells from evading immune surveillance. In 1998, the FDA approved the first HER2 targeting monoclonal antibody, called Herceptin® (trastuzumab) for the treatment of metastatic breast cancer. Later, in 2006, the drug got approved for HER2 positive early breast cancer. Following its success in treating breast cancer, significant efforts were made to evaluate its potential in other conditions involving HER2 alterations, such as overexpression, amplifications and other mutations. Eventually in 2010, the drug got FDA approval for HER2 positive metastatic stomach cancer as well. In addition to Herceptin, more than five drugs have been approved and about 70 candidates are under development for breast cancer, HER2-positive biliary tract, colorectal, non-small-cell lung and gastric cancers. Further, combinatorial studies of HER2 targeting therapeutics along with immune checkpoint inhibitors have also shown positive results across various disease indications.
Presently, several companies, including well-established players and new entrants, are actively engaged in developing the HER2 targeting therapies for a wide variety of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy and safety, and overall survival rate. The research activity has gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market has also witnessed substantial partnership activity over the last few years. Driven by the success of the currently available drugs / therapy products and the encouraging clinical trial results, the market is poised to witness healthy growth as multiple late stage drugs get approved and marketed over the next decade.
The “HER2 Targeting Therapies Market, 2021-2031” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for HER2 targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely selling price of HER2 targeting therapies, we have provided informed estimates on the evolution of the market for the period 2021-2031. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (breast cancer, gastric cancer head and neck cancer and lung cancer) [B] type of molecule (small molecule and biologic), [C] type of therapy (monotherapy, combination therapy and both), [D] route of administration (intravenous and oral) and [E] key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in the report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the HER2 targeting therapies market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to various aspects of cancer immunotherapy. The chapter lays emphasis on the role of targeting therapies in cancer treatment, including details on the HER2 mutations, mechanism of action of HER2 targeting therapies and the type of molecules that are developed / being developed. Further, it includes a discussion on the various challenges associated with the use of HER2 targeting therapies and highlights certain future perspectives.
Chapter 4 provides an overview of more than 200 molecules that are currently under development for the treatment of various cancer indications, along with a detailed analysis of these molecules, based on phase of development (marketed, clinical, preclinical and discovery stage) of lead candidates, type of molecule (biologic and small molecule), type of biologic (antibody drug conjugates, bispecific antibodies, CAR-T cell therapies, monoclonal antibodies, vaccines and others), type of therapy (monotherapy, combination therapy and both), target disease indication(s), therapeutic area(s) and route of administration (intradermal, intravenous, oral, and others). In addition, the chapter provides information on drug developer(s), highlighting their year of establishment, company size and geographical location of headquarters.
Chapter 5 includes detailed profiles of the key players (shortlisted based on number of pipeline products) engaged in the development of HER2 targeting therapies. Each profile includes a brief overview of the company, details on its product portfolio, and recent developments and an informed future outlook.
Chapter 6 provides a detailed analysis of more than 1,500 completed, ongoing and planned clinical studies of HER2 targeting therapies, based on the parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, target indication(s), focus areas, target therapeutic area(s), enrolled patient population and regional distribution of trials.
Chapter 7 provides an analysis of more than 1,300 grants awarded to research institutes engaged in the projects related to HER2 targeting therapies, in the period between 2018 and 2021 (till March) based on important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, focus area, prominent program officers, and recipient organizations.
Chapter 8 features a detailed analysis of the various partnerships and collaborations that have been established amongst the stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, and other agreements) adopted by stakeholders. It also includes analysis of the key companies that have established maximum number of partnerships, highlighting most popular type of molecule, and target disease indications.
Chapter 9 includes an insightful market forecast analysis, presenting the likely growth of HER2 targeting therapies market till the year 2031. In addition, we have provided inputs on the likely distribution of the market opportunity based on different target indications (breast cancer, gastric cancer, head and neck cancer and lung cancer), type of molecule (small molecule and biologic), type of therapy (monotherapy, combination therapy and both), route of administration (intravenous and oral) and key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 10 presents a case study on HER2 targeting biosimilars, highlighting market landscape of various biosimilars molecules that are developed / being developed. These molecules are further analyzed on the basis of several parameters, such as parent drug, phase of development and target disease indications. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.
Chapter 11 features a case study on companion diagnostic tests for that are developed / being developed corresponding to various HER2 targeting drug candidates, and their analysis on the basis of their commercial availability, assay technique used, corresponding drug candidate and target disease indication. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.
Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the HER2 targeting therapies market.
Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. HER2 Mutations
3.5. Overview of HER2 Targeting Therapies
3.5.1 Biologics Targeting HER2
3.5.1.1 Types of Products
3.5.2 Small Molecules Targeting HER2
3.5.2.1 Types of Products
3.6. Existing Challenges and Future Perspectives
4. CURRENT MARKET LANDSCAPE: MARKETED PRODUCTS AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. HER2 Targeting Therapies: Marketed Products and Development Pipeline
4.3. HER2 Targeting Therapies: Pipeline Analysis
4.3.1. Analysis by Current Status
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Route of Administration
4.3.8. Analysis by Phase of Development and Type of Molecule
4.3.9. Analysis by Phase of Development and Route of Administration
4.4. HER2 Targeting Therapies: Developer Landscape
4.4.1. Analysis by Type of Developer
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Geographical Location
4.4.5. Analysis by Company Size and Geographical Location
4.4.6. Leading Industry Players: Analysis by Number of Therapies
4.4.7. Leading Non-Industry Players: Analysis by Number of Therapies
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AstraZeneca
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. HER2 Targeting Therapies Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Boehringer Ingelheim
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. HER2 Targeting Therapies Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. GlaxoSmithKline
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. HER2 Targeting Therapies Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. MacroGenics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. HER2 Targeting Therapies Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Pfizer
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. HER2 Targeting Therapies Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Puma Biotechnology
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. HER2 Targeting Therapies Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Roche
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. HER2 Targeting Therapies Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. Seagen (previously Seattle Genetics)
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. HER2 Targeting Therapies Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. Triumvira Immunologics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. HER2 Targeting Therapies Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Zymeworks
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. HER2 Targeting Therapies Portfolio
5.11.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. HER2 Targeting Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase and Enrolled Patient Population
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Sponsor / Collaborator
6.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Disease Indication
6.3.10. Analysis by Target Therapeutic Area
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Enrolled Patient Population
7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. ` Scope and Methodology
7.3. HER2 Targeting Therapies: Analysis of Awarded Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Word Cloud Analysis: Emerging Focus Areas
7.3.10. Analysis by Study Section Involved
7.3.11. Popular NIH Departments: Analysis by Number of Grants Awarded
7.3.12. Prominent Program Officers: Analysis by Number of Grants Awarded
7.3.13. Analysis by Type of Recipient Organization
7.3.14. Popular Recipient Organizations: Analysis by Number of Grants Awarded
7.3.15. Regional Distribution of Recipient Organizations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. HER2 Targeting Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Intercontinental and Intracontinental Agreements
9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global HER2 Targeting Therapies Market, 2021-2031
9.4. HER2 Targeting Therapies: Individual Product Sales Forecasts
9.4.1. BAT8001 (Bio-Thera Solutions)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast
9.4.2. ENHERTU® (AstraZeneca)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast
9.4.3. Gilotrif® (Boehringer Ingelheim)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. KADCYLA™ (Roche)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast
9.4.5. MARGENZA™ (MacroGenics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast
9.4.6. RC48 (RemeGen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast
9.4.7. Nerlynx™ (Puma Biotechnology)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast
9.4.8. Perjeta® (Genentech, a Roche’s company)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast
9.4.9. SYD985 (Byondis)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast
9.4.10. MOBOCERTINIB (Takeda)
9.4.10.1. Target Patient Population
9.4.10.2. Sales Forecast
9.4.11. Tukysa® (Seagen)
9.4.11.1. Target Patient Population
9.4.11.2. Sales Forecast
9.4.12. Tyverb® (Roche)
9.4.12.1. Target Patient Population
9.4.12.2. Sales Forecast
9.4.13. Vizimpro® (Pfizer)
9.4.13.1. Target Patient Population
9.4.13.2. Sales Forecast
9.5. Global HER2 Targeting Therapies Market, 2021-2031: Distribution by Geography
9.5.1. HER2 Targeting Therapies Market in the North America, 2021-2031
9.5.2. HER2 Targeting Therapies Market in Europe, 2021-2031
9.5.3. HER2 Targeting Therapies Market in Asia Pacific, 2021-2031
9.5.4. HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031
9.5.5. HER2 Targeting Therapies Market in Latin America, 2021-2031
9.6. Global HER2 Targeting Therapies Market: Distribution by Target Disease Indication
9.6.1. Global HER2 Targeting Therapies Market for Breast Cancer, 2021-2031
9.6.2. Global HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031
9.6.3. Global HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031
9.6.4. Global HER2 Targeting Therapies Market for Lung Cancer, 2021-2031
9.7. Global HER2 Targeting Therapies Market: Distribution by Type of Molecule
9.7.1. Global HER2 Targeting Therapies Market for Biologics, 2021-2031
9.7.2. Global HER2 Targeting Therapies Market for Small Molecules, 2021-2031
9.8. Global HER2 Targeting Therapies Market: Distribution by Type of Therapy
9.8.1. Global HER2 Targeting Therapies Market for Monotherapy, 2021-2031
9.8.2. Global HER2 Targeting Therapies Market for Combination Therapy, 2021-2031
9.8.3. Global HER2 Targeting Therapies Market for Both Therapies, 2021-2031
9.9. Global HER2 Targeting Therapies Market: Distribution by Route of Administration
9.9.1. Global HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031
9.9.2. Global HER2 Targeting Therapies Market for Oral Therapies, 2021-2030
10. CASE STUDY: HER2 TARGETING BIOSIMILARS
10.1. Chapter Overview
10.2. HER2 Targeting Biosimilars: Marketed Products and Development Pipeline
10.3. HER2 Targeting Biosimilars: Pipeline Analysis
10.3.1. Analysis by Parent Drug
10.3.2. Analysis by Phase of Development of Biosimilar
10.3.3. Analysis by Target Disease Indication
10.4. HER2 Targeting Biosimilars: Developer Landscape
10.4.1. Analysis by Year of Establishment
10.4.2. Analysis by Geographical Location
10.4.3. Analysis by Company Size and Geographical Location
11. CASE STUDY: COMPANION DIAGNOSTICS FOR HER2 TARGETING THERAPIES
11.1. Chapter Overview
11.2. Companion Diagnostics for HER2 Targeting Therapies
11.2.1. Analysis by Commercial Availability of the Test
11.2.2. Analysis by Assay Technique Used
11.2.3. Analysis by Corresponding Drug Candidate
11.2.4. Analysis by Target Disease Indication
11.3. Companion Diagnostics for HER2 Targeting Therapies: Developer Overview
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geographical Location
12. CONCLUDING REMARKS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 HER2 Signaling Pathway
Figure 4.1 HER2 Targeting Therapies: Distribution by Current Status
Figure 4.2 HER2 Targeting Therapies: Distribution by Phase of Development
Figure 4.3 HER2 Targeting Therapies: Distribution by Type of Molecule
Figure 4.4 HER2 Targeting Therapies: Distribution by Type of Biologic
Figure 4.5 HER2 Targeting Therapies: Distribution by Type of Therapy
Figure 4.6 HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 4.7 HER2 Targeting Therapies: Distribution by Route of Administration
Figure 4.8 HER2 Targeting Therapies Developers: Distribution by Type of Developer
Figure 4.9 HER2 Targeting Therapies Developers: Distribution by Year of Establishment
Figure 4.10 HER2 Targeting Therapies Developers: Distribution by Company Size
Figure 4.11 HER2 Targeting Therapies Developers: Distribution by Geographical Location
Figure 4.12 HER2 Targeting Therapies Developers: Distribution by Company Size and Geographical Location
Figure 4.13 Leading Industry Players: Distribution by Number of Pipeline Candidates
Figure 4.14 Leading Non-Industry Players: Distribution by Number of Pipeline Candidates
Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year 2000-2021
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.7 Leading Players: Distribution by Number of Registered Trials
Figure 6.8 Word Cloud: Key Focus Areas
Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2018-2021
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2018-2021
Figure 7.3 Grant Analysis: Distribution by Funding Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Word Cloud Analysis: Emerging Focus Areas
Figure 7.10 Grant Analysis: Distribution by Study Section Involved
Figure 7.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.12 Popular NIH Departments: Distribution by Number of Grants
Figure 7.13 Prominent Program Officers: Distribution by Number of Grants Awarded
Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants Awarded
Figure 7.16 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Year of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Global HER2 Targeting Therapies Market, 2021-2031 (USD Million)
Figure 9.2 BAT8001 (Bio-Thera Solutions): Sales Forecast, till 2031 (USD Million)
Figure 9.3 ENHERTU® (AstraZeneca): Sales Forecast, till 2031 (USD Million)
Figure 9.4 Gilotrif® (Boehringer Ingelheim): Sales Forecast, till 2031 (USD Million)
Figure 9.5 KADCYLA™ (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.6 Margenza™ (MacroGenics): Sales Forecast, till 2031 (USD Million)
Figure 9.7 RC48 (RemeGen): Sales Forecast, till 2031 (USD Million)
Figure 9.8 Nerlynx™ (Puma Biotechnology): Sales Forecast, till 2031 (USD Million)
Figure 9.9 Perjeta® (Genentech, a Roche’s company): Sales Forecast, till 2031 (USD Million)
Figure 9.10 SYD985 (Byondis): Sales Forecast, till 2031 (USD Million)
Figure 9.11 MOBOCERTINIB (Takeda): Sales Forecast, till 2031 (USD Million)
Figure 9.12 Tukysa® (Seagen): Sales Forecast, till 2031 (USD Million)
Figure 9.13 Tyverb® (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.14 Vizimpro® (Pfizer): Sales Forecast, till 2031 (USD Million)
Figure 9.15 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Geography (USD Million)
Figure 9.16 HER2 Targeting Therapies Market in North America, 2021-2031 (USD Million)
Figure 9.17 HER2 Targeting Therapies Market in Europe, 2021-2031 (USD Million)
Figure 9.18 HER2 Targeting Therapies Market in Asia Pacific, 2021-2031 (USD Million)
Figure 9.19 HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031 (USD Million)
Figure 9.20 HER2 Targeting Therapies Market in Latin America, 2021-2031 (USD Million)
Figure 9.21 Global HER2 Targeting Therapies Market 2021 and 2031: Distribution by Target Disease Indication (USD Million)
Figure 9.22 HER2 Targeting Therapies Market for Breast Cancer, 2021-2031 (USD Million)
Figure 9.23 HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031 (USD Million)
Figure 9.24 HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031 (USD Million)
Figure 9.25 HER2 Targeting Therapies Market for Lung Cancer, 2021-2031 (USD Million)
Figure 9.26 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Molecule (USD Million)
Figure 9.27 HER2 Targeting Therapies Market for Biologics, 2021-2031 (USD Million)
Figure 9.28 HER2 Targeting Therapies Market for Small Molecules, 2021-2031 (USD Million)
Figure 9.29 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Therapy (USD Million)
Figure 9.30 HER2 Targeting Therapies Market for Monotherapy, 2021-2031 (USD Million)
Figure 9.31 HER2 Targeting Therapies Market for Combination Therapy, 2021-2031 (USD Million)
Figure 9.32 HER2 Targeting Therapies Market for Both, 2021-2031 (USD Million)
Figure 9.33 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Route of Administration (USD Million)
Figure 9.34 HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031 (USD Million)
Figure 9.35 HER2 Targeting Therapies Market for Oral Therapies, 2021-2031 (USD Million)
Figure 10.1 HER2 Targeting Biosimilars: Distribution by Parent Drug
Figure 10.2 HER2 Targeting Biosimilars: Distribution by Phase of Development of Biosimilar
Figure 10.3 HER2 Targeting Biosimilars: Distribution by Target Disease Indication
Figure 10.4 HER2 Targeting Biosimilar Developers: Distribution by Year of Establishment
Figure 10.5 HER2 Targeting Biosimilar Developers: Distribution by Geographical Location
Figure 10.6 HER2 Targeting Biosimilar Developers: Distribution by Company Size and Geographical Location
Figure 11.1 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Commercial Availability of the Test
Figure 11.2 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Assay Technique Used
Figure 11.3 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Corresponding Drug Candidate
Figure 11.4 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 11.5 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Year of Establishment
Figure 11.6 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Company Size
Figure 11.7 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Geographical Location
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Grant Analysis
Figure 12.4 Concluding Remarks: Partnerships and Collaborations
Figure 12.5 Concluding Remarks: Market Forecast
Table 4.1 HER2 Targeting Therapies: List of Therapies
Table 4.2 HER2 Targeting Therapies: List of Developers
Table 5.1 HER2 Targeting Therapies List of Companies Profiled
Table 5.2 AstraZeneca: Company Snapshot
Table 5.3 Drug Profile: ENHERTU®
Table 5.4 Drug Profile: AZD8931
Table 5.5 Boehringer Ingelheim: Company Snapshot
Table 5.6 Drug Profile: Gilotrif®
Table 5.7 GlaxoSmithKline: Company Snapshot
Table 5.8 Drug Profile: Tyverb®
Table 5.9 Drug Profile: SB719125
Table 5.10 MacroGenics: Company Snapshot
Table 5.11 Drug Profile: MARGENZA™
Table 5.12 Pfizer: Company Snapshot
Table 5.13 Drug Profile: Vizimpro®
Table 5.14 Drug Profile: CP-724714
Table 5.15 Drug Profile: PF-06804103
Table 5.16 Puma Biotechnology: Company Snapshot
Table 5.17 Drug Profile: Nerlynx™
Table 5.18 Roche: Company Snapshot
Table 5.19 Drug Profile: PERJETA®
Table 5.20 Drug Profile: Kadcyla™
Table 5.21 Drug Profile: RG6194
Table 5.22 Drug Profile: BTRC4017A
Table 5.23 Drug Profile: RG6148
Table 5.24 Seagen: Company Snapshot
Table 5.25 Drug Profile: Tukysa®
Table 5.26 Triumvira Immunologics: Company Snapshot
Table 5.27 Drug Profile: TAC01
Table 5.28 Drug Profile: TAC02
Table 5.29 ZymeWorks: Company Snapshot
Table 5.30 Drug Profile: ZW25
Table 5.31 Drug Profile: ZW49
The following companies and organizations have been mentioned in the report.